期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

2例非小细胞肺癌患者的个体化药学服务 被引量：1

Personalized Pharmaceutical Service for 2 Cases of Non-small Cell Lung Cancer Patients
下载PDF
导出
摘要 目的:为非小细胞肺癌(NSCLC)患者提供个体化药学服务。方法:对2例NSCLC患者进行治疗方案评估、用药监护、基因监测。结果:NSCLC患者进行基因检测后再服用埃克替尼近期效果好。结论:对NSCLC患者进行个体化治疗具有较好的近期疗效及安全性,耐受性良好。 Objective： To provide personalized pharmaceutical service for non-small cell lung cancer （NSCLC） patients. Methods ： Personalized pharmaceutical service was carried out for two NSCLC patients, including the assessment of therapy regimen, medication monitoring and genetie monitoring. Results： The recent effect in the patients was improved with genetic monitoring before the administration of ieotinib. Conclusion： Personalized chemotherapy has better efficacy, safety and toleration for NSCLC patients during the administration of icotinib.
作者 王丽萍 宋金春 周延安
机构地区 武汉大学人民医院药学部
出处 《中国药师》 CAS 2015年第7期1183-1184,1202,共3页 China Pharmacist
关键词 临床药师 药学服务 非小细胞肺癌 个体化 Clinical pharmacist Pharmaceutical service Non-small cell lung cancer, Personalization
分类号 R97 [医药卫生—药品]
  • 相关文献

参考文献19

  • 1.lemal A, Siegel R, Xu J, et al. Cancer statistics, 2010 [ J ]. CA Cancer J Glin ,2010 , 60 : 277-300.
  • 2Pugh TJ , Bebb G, Barclay L. Correlations of EGFR mutations and in- creases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients [ J ]. Cancer, 2007, 7 : 128.
  • 3Zhang WP, Stabile LP, Keohavong P, et al. Mutation and Polymor- phism in the EGFR-TK Domain Associated with Lung Cancer [ J ]. J Thorac Oncol,2006,1 (7) : 635-747.
  • 4Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005[J]. CA Cancer J Clin,2006 ,55 :10-30.
  • 5Li CG, Sun YH, Fang ZY, et al. Comprehensive Analysis of Epider- mal Growth Factor Receptor Gene Status in Lung Adenocarcinoma [J]. J Thorac Oncol. 2011.6.. 1016-1021.
  • 6Marchetti A, Martella C, Felicioni L, et al. EGFR small cell lung cancer: analysis of a large series of cases and develop- ment of a rapid and sensitive method for diagnostic screening with po- tential implications on pharmacologic treatment [ J ] . J Clin Oncol , 2005,23(4) : 857- 866.
  • 7Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological fea- tures associated with epidermal growth factor receptor gene mutations in lung cancers[J]. J Natl Cancer lnst ,2005 ,97 ( 5 ) :339-346.
  • 8Paez JG, Jame PA, Lee JC, et al. EGFR mutations in luing cancer: cor- relation with clinical response to gefitinib therapy [ J ]. Science, 2004, 304 ( 5676 ) : 1497-1500.
  • 9Lynch TJ, Bell DW, Sondella R, et al. Activating mutations in the epidermal growth factor receptor underlying reponsivenes of non-small- cell lung cancer to gefitinib [ J ]. N Engl J Med, 2004,350 ( 21 ) : 2129-2139.
  • 10Sreenath VS, Daphne WB, Settleman JH, et al. Epidermal growth factor receptor mutations in lung cancer[ J] . Nature, 2007, 7 ( 3 ) : 169- 183.

二级参考文献40

  • 1邬楠,王爱平,王印祥.表皮生长因子受体酪氨酸激酶抑制剂BPI-2009的抗肿瘤作用及其机制的研究[J].中国临床药理学与治疗学,2005,10(4):456-461. 被引量：7
  • 2吴健虹,谢秋玲,陈小佳,洪岸.表皮生长因子受体EGFR及其信号传导[J].生命科学,2006,18(2):116-122. 被引量：40
  • 3Tsao MS, Sakurada A, Cutz JC,et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome[J]. N EnglJ Med,2005,353(2):133--146.
  • 4Taron M, Ichinose Y, Rosell R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptorareassociatedwith improved survival in gefitinib-treated chemorefraetory lung adenocarcinomas[J]. Clin Cancer Res,2005,11 (16) :5878--5886.
  • 5Shigematsu H, Li L, Takao T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers[J]. J Natl Cancer I, 2005, 97(5) :339--347.
  • 6Kosaka T, Yatabe Y, Endoh Y,et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications[J]. Cancer Res, 2004,64(24) :8919- 8923.
  • 7Paez JG, Pasi AJ, Lee JC,et al. EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy[J]. Science, 2004,304(5676) : 1497 --1450.
  • 8Sreenath VS, Daphne WB, Settleman JH, et al. Epidermal growth factor receptor mutations in lung cancer[J]. Nature, 2007,7(3): 169-- 183.
  • 9Blackledge G, Verbuch S. Gefitinib ( Iressa , ZD1839) and new epidermal growth {actor receptor inhibitors[J]. Brit J Cancer, 2004, 90(3):566-- 572.
  • 10Cappuzzo F, Finocchiaro G, Metro G, et al. Clinical experience with gefitinib: An update[J]. Hematology,2006 ,58(1):31--45.

共引文献7

同被引文献5

引证文献1

二级引证文献6

中国药师
2015年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部